Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

Chris Mooney is a Pulitzer Prize-winning journalist and a CNN Climate contributor. He is currently a professor of practice in the Environmental Institute at the University of Virginia. Planet-warming ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

The AWS Certified Data Engineer Associate exam validates your ability to design, build, and maintain data processing systems that support analytics and business intelligence across AWS services. It ...

On Tuesday, Pennsylvania state lawmakers held a hearing with stakeholders to better understand how the state can prepare and manage the growth of data centers. FILE - A data center owned by Amazon Web ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Some economists are beginning to question the accuracy of recent U.S. inflation data after the federal government said staffing shortages hampered its ability to conduct a massive monthly survey. The ...

Structure content for AI search so it’s easy for LLMs to cite. Use clarity, formatting, and hierarchy to improve your visibility in AI results. In the SEO world, when we talk about how to structure ...

Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025, in San ...